Zobrazeno 1 - 10
of 352
pro vyhledávání: '"Peter M. Ellis"'
Autor:
Fiorella Di Pastena, Gregory Pond, Evangelia E. Tsakiridis, Andre Gouveia, Elham Ahmadi, Olga-Demetra Biziotis, Amr Ali, Anand Swaminath, Gordon Okawara, Peter M. Ellis, Bassam Abdulkarim, Naseer Ahmed, Andrew Robinson, Wilson Roa, Mario Valdes, Peter Kavsak, Marcin Wierzbicki, James Wright, Gregory Steinberg, Theodoros Tsakiridis
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Introduction Growth differentiation factor 15 (GDF15) is a cytokine of the TGFβ family. Here, we analyzed GDF15 levels in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who participated in OCOG-ALMERA (NCT02115464), a
Externí odkaz:
https://doaj.org/article/8cdf62e782fd48eb9e23a13a2e40ddfb
Autor:
Daniel Breadner, David M. Hwang, Don Husereau, Parneet Cheema, Sarah Doucette, Peter M. Ellis, Shaqil Kassam, Natasha Leighl, Donna E. Maziak, Shamini Selvarajah, Brandon S. Sheffield, Rosalyn A. Juergens
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6017-6031 (2024)
Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical for selecting biomarker-matched targeted
Externí odkaz:
https://doaj.org/article/f7cb34653c054cd781905d065bb3e78f
Autor:
Karen M. Zhang, Som D. Mukherjee, Gregory Pond, Michelle I. Roque, Ralph M. Meyer, Jonathan Sussman, Peter M. Ellis, Denise Bryant-Lukosius
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5354-5366 (2024)
Objective: Understanding both the positive and negative psychological outcomes among cancer patients during the pandemic is critical for planning post-pandemic cancer care. This study (1) examined levels of psychological distress and post-traumatic g
Externí odkaz:
https://doaj.org/article/47e462277fbb4c969bae1b867bc8413f
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9514-9529 (2023)
Background: Stage III nonsmall cell lung cancer (NSCLC) represents a heterogeneous group of patients. Many patients are treated with curative intent multimodality therapy, either surgical resection plus systemic therapy or chemoradiation plus immunot
Externí odkaz:
https://doaj.org/article/5c2d3d31fbf7475ab48192768a6bd832
Autor:
Barbara L. Melosky, Natasha B. Leighl, David Dawe, Normand Blais, Paul F. Wheatley-Price, Quincy S.-C. Chu, Rosalyn A. Juergens, Peter M. Ellis, Alexander Sun, Devin Schellenberg, Diana N. Ionescu, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6289-6315 (2023)
Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over th
Externí odkaz:
https://doaj.org/article/4018347cac8e41ddb2d0bdfcb844469e
Autor:
Peter A. Kavsak, PhD, Brock Hoard, BHSc, Katharine Mackett, BSc, MSc, Som D. Mukherjee, MD, MSc, Louise Bordeleau, MD, MSc, Peter M. Ellis, MD, PhD, Sukhbinder Dhesy-Thind, MD
Publikováno v:
CJC Open, Vol 5, Iss 8, Pp 658-660 (2023)
Externí odkaz:
https://doaj.org/article/af4d9c3fb61a4c839a48e48aeb3589d3
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9046-9065 (2022)
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. The standard-of-care treatment has not changed in years. Recent studies report improved progression-free survival (PFS) and overall survival (OS)
Externí odkaz:
https://doaj.org/article/d1ce9d3e5fc24c4eb97ae5b568df9cce
Autor:
Muhammad Mustafa Alhussein, MD, Abir Mokbel, MD, MSc, Tammy Cosman, RN(EC), PhD, Nazanin Aghel, MD, Eric H. Yang, MD, Som D. Mukherjee, MD, Susan Dent, MD, Peter M. Ellis, MBBS, MMed, PhD, Sukhbinder Dhesy-Thind, MD, MSc, Darryl P. Leong, MBBS, MPH, M. Biostat, PhD
Publikováno v:
CJC Open, Vol 3, Iss 11, Pp 1372-1382 (2021)
Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well es
Externí odkaz:
https://doaj.org/article/19ebfb6c8fb04bf8886b70411a949d57
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2778-2788 (2021)
Introduction: Treatment algorithms for small cell lung cancer (SCLC) are determined largely by the Veterans Affairs Lung Cancer Staging Group (VALCSG) staging (limited (LS) versus extensive (ES) stage). Relapse occurs frequently; however, patterns of
Externí odkaz:
https://doaj.org/article/1c290a2ebadc423cb5018d287091d06a
Autor:
Darryl P. Leong, MBBS, MPH, MBiostat, PhD, Tammy Cosman, PhD, Muhammad M. Alhussein, MD, Nidhi Kumar Tyagi, MBChB, Sarah Karampatos, MS, Carly C. Barron, MD, MS, Douglas Wright, MD, Vikas Tandon, MD, Patrick Magloire, MD, Philip Joseph, MD, David Conen, MD, MPH, P.J. Devereaux, MD, PhD, Peter M. Ellis, MBBS, MMed, PhD, Som D. Mukherjee, MD, MS, Sukhbinder Dhesy-Thind, MD, MS
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 1-10 (2019)
Objectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity. Background: Cardiotoxicity is the most common dose-limi
Externí odkaz:
https://doaj.org/article/853ece99bece43b0bf1ea0e673d30148